Bruce Barcott reviewed portions of the impressive intellectual property portfolio of GW Pharma (NASDAQ: GWPH), which the company summarized in its annual filing:
Our intellectual property portfolio at September 30, 2015, includes 60 patent families with issued and/or pending claims directed to plants, plant extracts, extraction technology, pharmaceutical formulations, drug delivery and the therapeutic uses of cannabinoids, as well as plant variety rights, know-how and trade secrets. From these families, as of September 30, 2015, we own 353 pending patent applications worldwide. Within the United States, we already have 32 issued patents with a further 32 pending patent applications under active prosecution. There are an additional 349 issued patents outside of the United States.
GW Pharma is in the news this week after its recent successful Phase 3 clinical trial for Epidiolex, which, if approved by the FDA, would be the first cannabis-derived pharmaceutical to be marketed in the United States. The company is aiming to treat rare forms of intractable childhood epilepsy, such as Dravet syndrome and Lennox-Gastaut syndrome.
Barcott explores the company’s assets beyond Epidiolex, discussing some of the more recently filed patents, including one granted in December relating “to the use of cannabinoid-containing extracts in the prevention or treatment of neural degeneration” and several others aimed at a broad array of diseases, included weight loss, psychotic disorders and constipation. He also discusses one that addresses treatment of a variety of cancers.
Read Bruce Barcott’s “How GW Pharma Could Use U.S. Patents to Shape the Future of Medical Cannabis”: https://www.leafly.com/news/headlines/how-gw-pharma-could-use-us-patents-to-shape-the-future-of-medical
